6.58
Schlusskurs vom Vortag:
$6.56
Offen:
$6.58
24-Stunden-Volumen:
2.53M
Relative Volume:
0.96
Marktkapitalisierung:
$1.05B
Einnahmen:
$418.84M
Nettoeinkommen (Verlust:
$-1.60M
KGV:
-638.83
EPS:
-0.0103
Netto-Cashflow:
$69.77M
1W Leistung:
-6.69%
1M Leistung:
-0.49%
6M Leistung:
-41.60%
1J Leistung:
-36.84%
Certara Inc Stock (CERT) Company Profile
Firmenname
Certara Inc
Sektor
Branche
Telefon
(415) 237-8272
Adresse
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CERT
Certara Inc
|
6.585 | 1.04B | 418.84M | -1.60M | 69.77M | -0.0103 |
|
VEEV
Veeva Systems Inc
|
179.20 | 29.72B | 3.20B | 908.91M | 1.42B | 5.4155 |
|
TEM
Tempus Ai Inc
|
50.41 | 8.85B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
38.21 | 7.42B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
77.15 | 6.56B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
24.07 | 4.72B | 1.10B | 112.09M | 283.19M | 0.6096 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-27 | Herabstufung | Craig Hallum | Buy → Hold |
| 2026-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-21 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-09-29 | Eingeleitet | Craig Hallum | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-08 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Hochstufung | UBS | Neutral → Buy |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | UBS | Neutral |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | Eingeleitet | Stephens | Overweight |
| 2023-04-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | Eingeleitet | Berenberg | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-01 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-11 | Hochstufung | Jefferies | Hold → Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-07-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Neutral |
| 2021-01-05 | Eingeleitet | Jefferies | Hold |
| 2021-01-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Certara Inc Aktie (CERT) Neueste Nachrichten
Avoiding Lag: Real-Time Signals in (CERT) Movement - Stock Traders Daily
Certara at Barclays Healthcare Conference: Strategic Growth and AI Integration - Investing.com
Dixon Mitchell Investment Counsel Inc. Purchases Shares of 866,380 Certara, Inc. $CERT - MarketBeat
Certara at Leerink Conference: Strategic Moves Amid Challenges - Investing.com
Certara at Leerink Conference: Strategic Moves Amid Challenges By Investing.com - Investing.com UK
Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials - Sahm
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And Latest Earnings Guidance - Sahm
Certara CEO Resnick Teases Regulatory Services Decision, Phoenix Cloud Push at TD Cowen Conference - Yahoo Finance
Certara appoints Jon Resnick as new CEO; reaffirms FY25 outlook - MSN
Will Certara Inc. stock outperform international peers2025 EndofYear Setup & Short-Term Trading Alerts - Naître et grandir
CERTCertara Inc Stock Price and Quote - Finviz
Certara, Inc. (CERT): Analysts Assign Equal-Weight Rating Amid Price Stagnation - 富途牛牛
Certara (CERT) Downgraded to Equal-Weight by Barclays | CERT Sto - GuruFocus
Certara's (CERT) Equal Weight Rating Reiterated at Barclays - MarketBeat
Forecasting The Future: 7 Analyst Projections For Certara - Benzinga
Barclays downgrades Certara stock rating on turnaround concerns By Investing.com - Investing.com South Africa
Barclays downgrades Certara stock rating on turnaround concerns - Investing.com
Certara at TD Cowen Conference: Strategic Focus and AI Integration By Investing.com - Investing.com Canada
Certara at TD Cowen Conference: Strategic Focus and AI Integration - Investing.com UK
Certara (CERT) Gains FDA Acceptance for PBPK Modeling in Drug Ap - GuruFocus
Certara, Inc. (CERT) Stock Analysis: Exploring a 38% Potential Upside in Health Information Services - DirectorsTalk Interviews
CERT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Certara Simcyp® simulator results replace ten human trials for chronic myeloid leukemia (CML) therapy asciminib - marketscreener.com
Certara Simcyp Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - Bitget
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - The Manila Times
FDA accepts virtual-patient data so leukemia drug avoids 10 trials - Stock Titan
Certara, Inc. $CERT Stock Holdings Boosted by Roubaix Capital LLC - MarketBeat
Certara Earnings Call: Software Strength Amid Transition - The Globe and Mail
Certara (CERT) director granted 5,547 restricted stock units - Stock Titan
Certara (CERT) director Arjun Bedi submits initial Form 3 insider filing - Stock Titan
Certara (CERT) Is Up 9.6% After Calling 2026 a Transition Year With Slower Growth Guidance - simplywall.st
Assessing Certara (CERT) Valuation After Recent Share Price Volatility - Yahoo Finance
Discipline and Rules-Based Execution in CERT Response - Stock Traders Daily
A Look At Certara (CERT) Valuation After Earnings Miss And 2026 Outlook Reset - simplywall.st
Certara, Inc. Hits 52-Week Low at USD 6.04 Amid Market Struggles - Markets Mojo
Certara (NASDAQ:CERT) Trading 6.1% HigherHere's What Happened - MarketBeat
Certara (CERT) Faces Downgrade Amid Strategic Uncertainty - GuruFocus
Certara (NASDAQ:CERT) Given New $8.00 Price Target at Barclays - MarketBeat
Certara stock downgraded at Craig-Hallum on growth concerns By Investing.com - Investing.com Canada
Certara stock downgraded at Craig-Hallum on growth concerns - Investing.com
Certara (NASDAQ:CERT) Rating Lowered to "Hold" at Craig Hallum - MarketBeat
Certara to Participate in Upcoming Investor Conferences - The Manila Times
Drug development firm Certara lines up three March investor talks - Stock Titan
Morgan Stanley Cuts Price Target on Certara to $11 From $12, Keeps Equalweight Rating - marketscreener.com
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara Q4 2025 slides: services growth offsets software weakness By Investing.com - Investing.com Australia
Certara stock hits 52-week low at 6.26 USD By Investing.com - Investing.com Australia
Certara (NASDAQ:CERT) Issues Earnings Results - MarketBeat
Leerink Maintains Outperform on Certara, Inc. (CERT) Feb 26 2026 PT $10 - Meyka
Certara Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Finanzdaten der Certara Inc-Aktie (CERT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):